Vilin Bio Med Limited’s Board approved the unaudited standalone and consolidated results for the half-year ended 30 September 2026 on 14 November 2026.
On a consolidated basis, the company reported:
- Revenue from operations: ₹32.60 Cr, up 237% year on year
- Profit before tax: ₹1.76 Cr, up 806% year on year
- Profit after tax: ₹1.28 Cr, up 743% year on year
Growth is measured against the half-year ended 30 September 2025. The consolidated results include the subsidiaries Axia Pharma Pvt. Ltd. and Vilo Speciality Pharma Pvt. Ltd.
Other NSE filings this fortnight:
- 10 November: Board meeting intimation for the results.
- 14 November: The Board approved the results with Limited Review Reports. It also approved the auditor-certified statement of deviation on preferential issue proceeds, and considered and approved the consolidated related-party transactions.

